Medical Oncology, Institut de Cancérologie Et d'Hématologie Universitaire de Saint-Étienne (ICHUSE), Centre Hospitalier Universitaire de Saint-Etienne, Service d'oncologie Médicale, Av. Albert Raimond, 42270, Saint-Priest-en-Jarez, France.
Groupe de Recherche Interdisciplinaire Francophone en Onco-Néphrologie (GRIFON), Paris, France.
Support Care Cancer. 2024 Nov 1;32(11):763. doi: 10.1007/s00520-024-08956-8.
Onco-nephrology is an emerging subspecialty aiming to better understand and prevent renal events in cancer patients. We assessed patients' knowledge about (1) oncological/hematological treatments induced renal toxicity and (2) kidney protective measures.
Adult patients receiving systemic anti-tumor treatments in multiple day hospital units in France answered a self-administered questionnaire about their knowledge and expectations related to treatment-associated renal toxicity.
In total, 621 questionnaires were collected in 8 units from November 2021 to January 2022. Among respondents, 84.5% were treated for a solid tumor. Overall, 34.3% (n = 208) patients reported they had some knowledge about potential renal adverse events related to their anticancer treatment, and 38.5% (n = 234) about kidney protection measures. Their referring oncologist or hematologist represented the commonest source of knowledge (67.8%). Sufficient hydration was cited as a kidney protection measure by 93.2% (n = 218) of patients declaring some knowledge about renal toxicity; prevention of nausea/vomiting by 52.6% (n = 123). Consumption of still and alkaline water was chosen by respectively 64.4% (n = 400) and 16.8% (n = 104) of participants to correct dehydration. A majority of patients expressed strong interest for receiving more information about renal toxicity and prevention: median Likert scale score was 10/10 (Q1-Q3, 5-10), with online resources mentioned as the most desired source of information.
One-third of patients declared they had some knowledge about potential renal toxicity of their oncologic treatment and the ways to prevent them, especially regarding hydration. However, a majority expressed interest for dedicated information, which conducted to the elaboration of free online educational sheets for patients.
肿瘤肾脏病学是一个新兴的亚专业领域，旨在更好地了解和预防癌症患者的肾脏事件。我们评估了患者对（1）肿瘤/血液学治疗引起的肾毒性和（2）肾脏保护措施的了解程度。
在法国的多个日间医院病房接受全身抗肿瘤治疗的成年患者回答了一份关于他们对与治疗相关的肾毒性相关的知识和期望的自我管理问卷。
2021 年 11 月至 2022 年 1 月，8 个单位共收集了 621 份问卷。在答卷者中，84.5%的人患有实体瘤。总体而言，34.3%（n=208）的患者报告说他们对与抗癌治疗相关的潜在肾脏不良事件有一些了解，38.5%（n=234）对肾脏保护措施有一些了解。他们的主治肿瘤医生或血液科医生是最常见的知识来源（67.8%）。足够的水化被 93.2%（n=218）的患者认为是预防肾毒性的措施之一；52.6%（n=123）的患者认为预防恶心/呕吐是预防肾毒性的措施之一。分别有 64.4%（n=400）和 16.8%（n=104）的参与者选择饮用静止水和碱性水来纠正脱水。大多数患者对接受更多关于肾毒性和预防的信息表现出强烈的兴趣：Likert 量表评分中位数为 10/10（Q1-Q3，5-10），在线资源是最受欢迎的信息来源。
三分之一的患者表示，他们对肿瘤治疗的潜在肾毒性及其预防方法有一定的了解，特别是关于水化。然而，大多数人对专门的信息表示了兴趣，这导致为患者编写了免费的在线教育资料。
